.

Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Teva
McKesson
Baxter
Deloitte
Boehringer Ingelheim
Cerilliant
Fish and Richardson
Citi
Queensland Health

Generated: September 21, 2017

DrugPatentWatch Database Preview

ANGELIQ Drug Profile

« Back to Dashboard

What is the patent landscape for Angeliq, and when can generic versions of Angeliq launch?

Angeliq is a drug marketed by Bayer Hlthcare and is included in one NDA. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has sixty-four patent family members in thirty-two countries.

The generic ingredient in ANGELIQ is drospirenone; estradiol. There are ten drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the drospirenone; estradiol profile page.

Summary for Tradename: ANGELIQ

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Clinical Trials: see list7
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ANGELIQ at DailyMed

Pharmacology for Tradename: ANGELIQ

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare
ANGELIQ
drospirenone; estradiol
TABLET;ORAL021355-001Feb 29, 2012RXYesNo► Subscribe► SubscribeY ► Subscribe
Bayer Hlthcare
ANGELIQ
drospirenone; estradiol
TABLET;ORAL021355-002Sep 28, 2005RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ANGELIQ

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer Hlthcare
ANGELIQ
drospirenone; estradiol
TABLET;ORAL021355-002Sep 28, 2005► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ANGELIQ

Drugname Dosage Strength RLD Submissiondate
drospirenone and estradiolTablets0.25 mg/0.5 mgAngeliq1/8/2015
drospirenone and estradiolTablets0.5 mg/1 mgAngeliq12/26/2007

Non-Orange Book Patents for Tradename: ANGELIQ

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,121,465 Process for production drospirenone and intermediate products of the process► Subscribe
9,592,245Very low-dosed solid oral dosage forms for HRT► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ANGELIQ

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)9806738► Subscribe
Turkey9900262► Subscribe
Germany59706887► Subscribe
Guatemala201200281► Subscribe
Israel127963► Subscribe
Portugal918791► Subscribe
Hong Kong1021190► Subscribe
Australia4014497► Subscribe
Brazil112012026115► Subscribe
Iceland4965► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ANGELIQ

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0022France► SubscribePRODUCT NAME: ESTRADIOL ANHYDRE DROSPIRENONE; REGISTRATION NO/DATE IN FRANCE: NL 28661 DU 20040316; REGISTRATION NO/DATE AT EEC: RVG 27505 DU 20021211
C/GB04/032United Kingdom► SubscribePRODUCT NAME: ESTRADIOL, OPTIONALLY IN THE FORM OF A HYDRATE, TOGETHER WITH DROSPIRENONE; REGISTERED: NL RVG 27505 20021211; UK PL 00053/0341 20040310
2006009Lithuania► SubscribePRODUCT NAME: DROSPIRENONUM; NAT. REGISTRATION NO/DATE: LT/1/06/0520/001, 2006 07 10 LT/1/06/0520/002, 2006 07 10 LT/1/06/0520/003, 2006 07 10 LT/1/06/0520/004 20060710; FIRST REGISTRATION: RVG 31781 20050804
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Cerilliant
Novartis
Mallinckrodt
Cipla
Dow
Teva
Baxter
UBS
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot